Rx-360 consortium names directors

Lynne Byers of GSK to become chair in January

The Rx-360 consortium of pharmaceutical and biotechnology companies, which was formed in 2009 to support an industry-wide commitment to ensuring patient safety by enhancing quality and authenticity throughout the supply chain, has named its new board of directors.

From 1 January 2011 Lynne Byers of GSK will become chair, with Al Kentrup of Prizer as vice-chair.

Supporting them as board members are:

  • Matt Anderson (Baxter)
  • Tom Beil (Sigma Aldrich)
  • Janice Berger (AstraZeneca)
  • Jack Brinnier (Watson)
  • Thomas Crispin (Bayer)
  • Heike Falkenhagen (Boehringer Ingelheim)
  • Chris Franco (Takeda)
  • Burghard Frieberg (Merck KGaA)
  • Natalie Garrett (Abbott)
  • David Haggard (Merck)
  • Ernie Kelly (Cephalon)
  • Diane Petitti (Amylin)
  • Melissa Seymour (Biogen Idec)
  • Nick Shackley (BASF)
  • Paul Smaltz (Mallinckrodt Baker)
  • Martin Van Trieste (Amgen)
  • Guy Villax (Hovione)
  • Andreas Wirth (Novartis)

Current and founding chairman Martin Van Trieste of Amgen, said: ‘This is a strong board; we have 20 committed individuals who combine a wealth of experience and are serving to protect the pharmaceutical supply chain.’

‘Five board members represent suppliers and 15 represent members who are manufacturers of pharmaceuticals. We have representation from the three main regions and from both innovators and generics – this is a demonstration of the inclusive nature of Rx-360.’

You may also like

Ingredients

Rx-360 publishes audit standards

Issued for APIs and intermediates together with two new audit tools
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Distribution

Tower Cold Chain launches live tracking and monitoring for pharmaceutical distribution

The upgrade allows customers to access real-time insights into shipments, facilitating the optimisation of cold chain processes
Manufacturing

Europe’s generic medicines are disappearing, study finds

Over a ten year period, the number of generic medicines withdrawn from the market increased by 12%
Pharmaceutical

Polyplus introduces off-the-shelf plasmids for AAV2 production; plans to expand plasmid portfolio to support full range of AAV serotypes in 2024

Polyplus (part of Sartorius), a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has launched pPLUS® AAV-RC2, a RepCap plasmid for adeno-associated virus vector 2 (AAV2) production
Subscribe now